Open access
Open access
Powered by Google Translator Translator

Family Medicine

CDC Report: COVID-19 vaccine safety in children aged 5–11 Years.

9 Jan, 2022 | 01:09h | UTC

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021 – CDC Morbidity and Mortality Weekly Report

Commentary: COVID-19 vaccine appears safe in children aged 5–11 Years – News Medical

 

Commentary on Twitter

 

New CDC Guidance shortens isolation and quarantine period for Covid-19; patients that tested positive should isolate for 5 days and, if asymptomatic after this period, can leave isolation if they can continue to mask for 5 days to minimize the risk of infecting others.

9 Jan, 2022 | 01:13h | UTC

CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population – Centers for Disease Control and Prevention

See also: Quarantine and Isolation – Centers for Disease Control and Prevention

Commentaries:

Facing criticism, CDC updates Covid-19 isolation recommendations with guidance on testing – CNN

CDC posts rationale for shorter isolation, quarantine – Associated Press

Covid-19: CDC shortens isolation period as US cases hit record high – The BMJ

Shortened CDC COVID isolation guide draws sharply mixed reviews – CIDRAP

New CDC isolation guidelines raise concerns among health experts – NPR

CDC Reduces Recommended Isolation Time for People With COVID-19 – HealthDay

COVID isolation and quarantine period for general population shortened by CDC – News Medical

CDC shortens recommended Covid-19 isolation and quarantine time – CNN

CDC cuts the recommended isolation and quarantine periods for coronavirus infections – NPR

US officials recommend shorter COVID isolation, quarantine – Associated Press

See new recommendations from other countries:

France cuts isolation times and plans crackdown on unvaccinated amid record surge in Covid cases – CNN

Covid: Self-isolation cut from 10 days to seven with negative tests – BBC

 

CDC Study: A test to stay strategy (allowing close contacts with masked COVID-19 exposures to remain in school) was very efficacious in preventing further school spread and allowed children to stay in the classroom as an alternative to home quarantine.

9 Jan, 2022 | 01:07h | UTC

Evaluation of Test to Stay Strategy on Secondary and Tertiary Transmission of SARS-CoV-2 in K–12 Schools — Lake County, Illinois, August 9–October 29, 2021 – CDC Morbidity and Mortality Weekly Report

Related CDC Study: Evaluation of a Test to Stay Strategy in Transitional Kindergarten Through Grade 12 Schools — Los Angeles County, California, August 16–October 31, 2021 – CDC Morbidity and Mortality Weekly Report

Related CDC Guidance:

What You Should Know About COVID-19 Testing in Schools – Centers for Disease Control and Prevention

Science Brief: Transmission of SARS-CoV-2 in K-12 Schools and Early Care and Education Programs – Updated – Centers for Disease Control and Prevention

Commentary: ‘Test-to-stay’ works to keep students in school safely, CDC director says – CNN

Related:

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

 

Commentary on Twitter

 

Diagnostics for COVID-19: moving from pandemic response to control.

8 Jan, 2022 | 23:33h | UTC

Diagnostics for COVID-19: moving from pandemic response to control – The Lancet

 

Commentary on Twitter

 

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

9 Jan, 2022 | 01:05h | UTC

Risk of myocarditis following sequential COVID-19 vaccinations by age and sex – medRxiv

Commentary: An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older – News Medical

Note: this study is an updated analysis of a recent study published in Nature Medicine; see below:

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

 

Guideline: ADA 2022 Standards of Medical Care in Diabetes.

24 Dec, 2021 | 13:38h | UTC

Guideline Homepage: ADA 2022 Standards of Medical Care in Diabetes – American Diabetes Association

Introduction: Standards of Medical Care in Diabetes—2022

Summary of Revisions: Standards of Medical Care in Diabetes—2022

Standards of Medical Care in Diabetes—2022 Guideline Abridged for Primary Care Providers

Video Summary: Standards of Care in Diabetes – 2022

  1. Improving Care and Promoting Health in Populations
  2. Classification and Diagnosis of Diabetes 
  3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities
  4. Comprehensive Medical Evaluation and Assessment of Comorbidities
  5. Facilitating Behavior Change and Well-being to Improve Health Outcomes
  6. Glycemic Targets
  7. Diabetes Technology
  8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes
  9. Pharmacologic Approaches to Glycemic Treatment
  10. Cardiovascular Disease and Risk Management
  11. Chronic Kidney Disease and Risk Management
  12. Retinopathy, Neuropathy, and Foot Care
  13. Older Adults
  14. Children and Adolescents
  15. Management of Diabetes in Pregnancy
  16. Diabetes Care in the Hospital
  17. Diabetes Advocacy

 

Commentaries on Twitter

 

AHA Scientific Statement | Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy.

8 Jan, 2022 | 23:16h | UTC

Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association – Hypertension

News Release: High blood pressure treatment in pregnancy is safe, prevents maternal heart risks – American Heart Association

 

Commentary on Twitter

 

AAN Guideline: Oral and topical treatment of painful diabetic polyneuropathy.

8 Jan, 2022 | 23:18h | UTC

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee – Neurology

News Release: AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy – American Academy of Neurology

 

New AAP Guidance recommends routine HIV screening to all youth 15 years or older.

8 Jan, 2022 | 23:13h | UTC

Adolescents and Young Adults: The Pediatrician’s Role in HIV Testing and Pre- and Postexposure HIV Prophylaxis – Pediatrics

Commentary: Pediatricians Can Play Key Role in HIV Testing, Prophylaxis – HealthDay

 

FDA approves first injectable treatment for HIV pre-exposure prevention.

8 Jan, 2022 | 23:04h | UTC

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention – U.S. Food & Drug Administration

Commentaries:

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases

A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR

Related:

CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents

Study Shows High Burden of STI Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection

USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection

British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (several guidelines on the subject)

New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required

 

RCT: Long-term supplementation with marine Omega-3 fatty acids does not reduce the risk of depressive symptoms.

8 Jan, 2022 | 23:10h | UTC

Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Clinical trial reveals that omega-3 fish oil supplements do not help prevent depression – Massachusetts General Hospital

 

In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.

8 Jan, 2022 | 22:37h | UTC

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation – JAMA

Commentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD

Related:

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation – American Journal of Medicine

Observational Study Suggests Apixaban May Be a Better Choice than Rivaroxaban for Patients with Atrial Fibrillation

 

AAP Interim guidance on supporting the emotional and behavioral health needs of children, adolescents, and families during the COVID-19 pandemic.

17 Dec, 2021 | 09:57h | UTC

Interim Guidance on Supporting the Emotional and Behavioral Health Needs of Children, Adolescents, and Families During the COVID-19 Pandemic – American Academy of Pediatrics

Commentary: AAP Issues Guidance for Children’s Emotional Needs During COVID-19 – HealthDay

 

Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.

8 Jan, 2022 | 22:36h | UTC

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine

Commentaries:

Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist

Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology

 

RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.

17 Dec, 2021 | 09:50h | UTC

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Invited commentary: Anticoagulation in COVID-19 – The Lancet

 

Commentary on Twitter

 

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

17 Dec, 2021 | 09:52h | UTC

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)

 

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

17 Dec, 2021 | 10:01h | UTC

Interim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization

Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post

 

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

17 Dec, 2021 | 09:54h | UTC

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine

Commentaries:

Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP

Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine

Related: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (several articles on the subject)

 

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show.

17 Dec, 2021 | 09:48h | UTC

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ

See also: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study

 

Commentary on Twitter

 

NICE Guideline | Type 2 diabetes in adults: management.

17 Dec, 2021 | 08:45h | UTC

Type 2 diabetes in adults: management – National Institute for Health and Care Excellence

Related: Guideline: ADA 2021 Standards of Medical Care in Diabetes

 

NICE Guideline | Fever in under 5s: assessment and initial management.

17 Dec, 2021 | 08:44h | UTC

Fever in under 5s: assessment and initial management – National Institute for Health and Care Excellence

Related: AAP Guideline: Evaluation and management of well-appearing febrile infants 8 to 60 days old.

 

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.

17 Dec, 2021 | 08:36h | UTC

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Commentary on Twitter

 

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

16 Dec, 2021 | 09:52h | UTC

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Related:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

M-A: Global percentage of asymptomatic SARS-CoV-2 infections around 40%.

15 Dec, 2021 | 08:47h | UTC

Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: ~40 Percent With Confirmed COVID-19 Are Asymptomatic – HealthDay

 

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

15 Dec, 2021 | 08:43h | UTC

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection – Nature Medicine

News release: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford

 

Commentaries on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.